297 related articles for article (PubMed ID: 18418429)
21. Evaluation of endothelial dysfunction, lipid metabolism in women with polycystic ovary syndrome: relationship of paraoxonase 1 activity, malondialdehyde levels, low-density lipoprotein subfractions, and endothelial dysfunction.
Bayram F; Kocer D; Ozsan M; Muhtaroglu S
Gynecol Endocrinol; 2012 Jul; 28(7):497-501. PubMed ID: 22703625
[TBL] [Abstract][Full Text] [Related]
22. [Exploration of the classification of polycystic ovarian syndrome].
Lin JF; Li X; Zhu MW
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
[TBL] [Abstract][Full Text] [Related]
23. Obesity, free testosterone, and cardiovascular risk factors in adolescents with polycystic ovary syndrome and regularly cycling adolescents.
Glueck CJ; Morrison JA; Friedman LA; Goldenberg N; Stroop DM; Wang P
Metabolism; 2006 Apr; 55(4):508-14. PubMed ID: 16546482
[TBL] [Abstract][Full Text] [Related]
24. Relation between C-reactive protein and body mass index in patients with polycystic ovarian syndrome.
Moradi S; Mollabashi M; Kerman SR
Gynecol Endocrinol; 2011 Jul; 27(7):480-5. PubMed ID: 20836727
[TBL] [Abstract][Full Text] [Related]
25. Hypoadiponectinemia: a useful marker of dyslipidemia in women with polycystic ovary syndrome.
Chang CY; Chen MJ; Yang WS; Yeh CY; Ho HN; Chen SU; Yang YS
Taiwan J Obstet Gynecol; 2012 Dec; 51(4):583-90. PubMed ID: 23276562
[TBL] [Abstract][Full Text] [Related]
26. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
27. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M
Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
[TBL] [Abstract][Full Text] [Related]
28. Retinol-binding protein in nonobese women with polycystic ovary syndrome.
Lee JW; Im JA; Lee DC; Lee HR; Shim JY
Clin Endocrinol (Oxf); 2008 May; 68(5):786-90. PubMed ID: 17986278
[TBL] [Abstract][Full Text] [Related]
29. Dyslipidemia in women with polycystic ovary syndrome: incidence, pattern and predictors.
Rocha MP; Marcondes JA; Barcellos CR; Hayashida SA; Curi DD; da Fonseca ÂM; Bagnoli VR; Baracat EC
Gynecol Endocrinol; 2011 Oct; 27(10):814-9. PubMed ID: 20807166
[TBL] [Abstract][Full Text] [Related]
30. [Correlation between hormonal and metabolic profiles in women with polycystic ovary syndrome].
Esposito V; Federico P; Lo Iudice G; Rispoli C; Sabatino P; D'Alessandro B
Minerva Endocrinol; 1992; 17(1):21-9. PubMed ID: 1495451
[TBL] [Abstract][Full Text] [Related]
31. Differences in low-grade chronic inflammation and insulin resistance in women with previous gestational diabetes mellitus and women with polycystic ovary syndrome.
Thomann R; Rossinelli N; Keller U; Tirri BF; De Geyter C; Ruiz J; Kränzlin M; Puder JJ
Gynecol Endocrinol; 2008 Apr; 24(4):199-206. PubMed ID: 18382906
[TBL] [Abstract][Full Text] [Related]
32. Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment.
Glintborg D; Højlund K; Andersen M; Henriksen JE; Beck-Nielsen H; Handberg A
Diabetes Care; 2008 Feb; 31(2):328-34. PubMed ID: 18000176
[TBL] [Abstract][Full Text] [Related]
33. Increased circulating soluble P-selectin in polycystic ovary syndrome.
Yildiz BO; Bozdag G; Harmanci A; Otegen U; Boynukalin K; Vural Z; Kirazli S; Haznedaroglu IC; Yarali H
Fertil Steril; 2010 May; 93(7):2311-5. PubMed ID: 19261277
[TBL] [Abstract][Full Text] [Related]
34. Serum leptin levels correlate with clinical and biochemical indices of insulin resistance in women with polycystic ovary syndrome.
Pehlivanov B; Mitkov M
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):153-9. PubMed ID: 19340711
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome.
Lankarani M; Valizadeh N; Heshmat R; Peimani M; Sohrabvand F
Gynecol Endocrinol; 2009 Aug; 25(8):504-7. PubMed ID: 19499403
[TBL] [Abstract][Full Text] [Related]
36. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
Barber TM; Wass JA; McCarthy MI; Franks S
Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
[TBL] [Abstract][Full Text] [Related]
37. Lipid accumulation product index: a reliable marker of cardiovascular risk in polycystic ovary syndrome.
Wiltgen D; Benedetto IG; Mastella LS; Spritzer PM
Hum Reprod; 2009 Jul; 24(7):1726-31. PubMed ID: 19329517
[TBL] [Abstract][Full Text] [Related]
38. Metabolic syndrome in adolescents with polycystic ovary syndrome.
Vrbíková J; Zamrazilová H; Sedláčková B; Šnajderová M
Gynecol Endocrinol; 2011 Oct; 27(10):820-2. PubMed ID: 20807165
[TBL] [Abstract][Full Text] [Related]
39. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Katsikis I; Piperi C; Alexandraki K; Panidis D
Clin Endocrinol (Oxf); 2007 Jan; 66(1):103-9. PubMed ID: 17201808
[TBL] [Abstract][Full Text] [Related]
40. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
Shi Y; Guo M; Yan J; Sun W; Zhang X; Geng L; Xu L; Chen Z
Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
